One of 2024's best stocks is at an intriguing entry pointHims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss drug craze -- is taking a hit after the Food and Drug Administration (FDA) announced Eli Lilly's (LLY) weight-loss drug shortage was resolved. HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth ...

Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven’t exactly been performing well as of late.There’s no big mystery as to why — the COVID-19 pandemic saw a sudden surge in utilization, but as soon as in-person healthcare services resumed, demand dried up significantly. On top of that, this is a field with no shortage of regulatory and legal risks — while the rap ...

Core Insights - Hims & Hers Health, Inc. has shown significant growth in the personalized healthcare market, with shares rising 43% in the past month compared to the industry's 5.5% growth [1] - The company reported third-quarter revenues of $401.6 million, a 77% year-over-year increase, with earnings per share (EPS) of 32 cents meeting analyst expectations [2] - Hims & Hers has over 2 million subscribers, with more than 50% utilizing personalized health solutions [2] Financial Performance - Revenue for 2024 is projected to exceed $1.5 billion, with EBITDA margins expected to reach 15% by year-end [4] - The Zacks Consensus Estimates for 2025 revenues is $2.05 billion, indicating a 40.2% year-over-year growth [4] Growth Drivers - The company's innovative personalized healthcare model and advancements in weight loss and dermatology offerings are key growth drivers [3] - The weight loss category, particularly through GLP-1 medications, has achieved a $100 million annual revenue run rate in less than a year [6][7] - Hims & Hers plans to expand its weight loss offerings with the introduction of liraglutide in 2025 [7] Personalized Solutions - Hims & Hers has broadened its personalized solutions across five core specialties: mental health, sexual health, weight loss, dermatology, and wellness [8] - Over 85% of dermatology subscribers opted for personalized solutions in Q2 2024, indicating strong demand [9] Technology and Customer Engagement - Proprietary AI tools and machine learning capabilities enhance customer experiences and improve treatment adherence [10][11] - Subscribers engage with their providers an average of three times within the first four weeks of treatment, fostering trust and satisfaction [10] Market Position and Strategy - Hims & Hers aims to democratize healthcare by providing personalized solutions at mass-market prices, targeting underserved populations [17] - The company plans to scale its offerings geographically and across new specialties, with a goal to significantly increase its subscriber base by 2030 [15][16] Competitive Landscape - The personalized healthcare market is becoming increasingly competitive, with established players posing a threat to Hims & Hers' growth [20] - Continued innovation and differentiation through superior customer experience and affordability are essential for maintaining market position [21] Challenges - Hims & Hers faces challenges related to supply-chain integrity, regulatory pressures, and competition [22] - The company has mitigated some operational challenges through compounded alternatives but must navigate a complex regulatory landscape [22] Conclusion - Hims & Hers Health is positioned for long-term success in the personalized healthcare sector, leveraging innovation, technology, and a commitment to affordability [23]

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.Hims & Hers Health, Inc. (NYSE: HIMS ) is a San Francisco-based $6.7-billion market cap firm that provides a telehealth solution that links people with qualified doctors in the US, the UK, and throughoutHe leads the investing group Beyond the Wall In ...

Hims & Hers Health, Inc. (NYSE: HIMS ) stock is still substantially undervalued even after a massive YTD rally. A 35% discount looks extremely attractive because HIMS is a very promising business that successfully capitalizes on robust secular trendsComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies p ...

The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform. As an avid supporter of telemedicine, his appointment as the FDA chief, upon Senate approval, would benefit telehealth companies and their stocks. Here are two telehealth stocks in th ...

Hims & Hers Health, Inc. (NYSE: HIMS ) leads the fast-growing health and wellness market using its technology-based platform to offer personalized, accessible care. The company has been a pioneer in subscription-based healthcare, driving substantial revenue and subscriberYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certifi ...

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.Shares of Hims & Hers (HIMS 0.61%) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a business similar to Hims & Hers. In this video, Travis Hoium covers why this is important and why the stock is moving as fast as it is.*Stock prices used were end-of-day prices of Nov. 25, 2024. The vi ...

Schaeffer's Weekend Trader subscribers scored a big win just in time for Thanksgiving. Bulls doubled their money with our Hims & Hers Health Inc (NYSE:HIMS) February 17 call recommendation in just over one week, so now is a good time to see how the trade played out. At the time of our recommendation on Nov. 17, HIMS had just nabbed an all-time high after a push above $30, which was three times its 2019 initial public offering (IPO) price. A sharp pullback followed that peak, which may have been exaggerated ...

Telehealth stock Hims & Hers Health Inc (NYSE:HIMS) nabbed an all-time high last week after a push above $30, which happens to be three times its 2019 initial public offering (IPO) price. The peak was followed by a sharp pullback, which may have been exaggerated by an unwinding of long positions associated with expiring November call open interest (OI) and delta-hedge selling related to heavy out-of-the-money OI in 11/22 through standard December options. There is plenty of support lingering below to captur ...